The "Graft Versus Host Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Global ...

Tr1X said that TRX103 could enhance transplant accessibility for patients who lack a matched donor while also minimising GvHD risks. The drug is an off-the-shelf engineered T cell product derived ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

Itolizumab showed significant long-term benefits in acute GVHD, improving complete response duration and failure-free survival. Equillium, Inc. seeks Breakthrough Therapy designation and Accelerated ...

Allogeneic hematopoietic stem cell transplantation (HSCT) is an important and potentially curative treatment of haematological malignancies, but GvHD and infections affect outcomes. We present ...

The TRX103 Phase 1/2a clinical trial is being led by Maria Grazia Roncarolo, MD, co-founder, president and head of R&D at Tr1X, with patients enrolling at leading stem cell transplant centers across ...